All

The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines and legal actions taken by regulatory authorities across the world.

The WHO Pharmaceuticals Newsletter No 2. 2017 is available here.

 

Please assist the International Society of Oncology Pharmacy Practitioners (ISOPP) gather some baseline information with respect to advocacy activities related to drug access that Oncology Pharmacists engage in at the institutional/regional//national and international level(s) by completing a 5 minute survey by March 31, 2017.

 
The purpose of Hematopoietic Stem Cell Transplantation (HSCT) E-learning Tool is to provide basic knowledge to hospital and community pharmacists involved in the pharmaceutical care for HSCT patients.

Become a member to have access!

 

The American Society of Clinical Oncology’s (ASCO) recently published antiemetic guideline update excluded oncology pharmacists from the targeted audience. A letter to the Editor was submitted to the Journal of Clinical Oncology by the Canadian Association of Pharmacy Oncology (CAPhO), in collaboration with HOPA and ISOPP, to bring awareness to the omission.

 

This guideline offers best practice advice on the care of all people who are using medicines and also those who are receiving suboptimal benefit from medicines. 

The full list of recommendations is in section 1.

 

The combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) was held on February 11 - 15, 2015, in San Diego, California.

 

This report explores the range of possible causes that might explain observed international variations in the usage of medicines for selected disease areas: dementia, osteoporosis, cancer, diabetes and hepatitis C. 

 

An Opioid-Related Death in a Small Community Hospital. See full text here.

 

Review conclude that cognitive-behavioural training as well as mental and physical relaxation all reduce stress moderately.

 
The ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) features updates in the diagnosis, s